Effect of Simvastatin on Plasma Homocysteine Levels and Its Modification by MTHFR C677T Polymorphism in Chinese Patients with Primary Hyperlipidemia

Shanqun Jiang,Qianru Chen,Scott A. Venners,Guisheng Zhong,Yi‐Hsiang Hsu,Xing Huang,Xiaobin Wang,Xiping Xu

DOI: https://doi.org/10.1111/cdr.12002

2012-01-01

Cardiovascular Therapeutics

Abstract:Cardiovascular TherapeuticsVolume 31, Issue 4 p. e27-e33 Original Research ArticleFree Access Effect of Simvastatin on Plasma Homocysteine Levels and Its Modification by MTHFR C677T Polymorphism in Chinese Patients with Primary Hyperlipidemia Shanqun Jiang, Corresponding Author Shanqun Jiang School of Life Sciences, Anhui University, Hefei, China Institute of Biomedicine, Anhui Medical University, Hefei, China Correspondence Shanqun Jiang, PhD., School of Life Sciences, Anhui University, 3 Feixi Road, PO Box 41, Hefei 230039, China. Tel.: 86-13956059590 Fax: 86-551-5107354 E-mail: shanqun@gmail.comSearch for more papers by this authorQianru Chen, Qianru Chen School of Life Sciences, Anhui University, Hefei, ChinaSearch for more papers by this authorScott A. Venners, Scott A. Venners Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CanadaSearch for more papers by this authorGuisheng Zhong, Guisheng Zhong Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USASearch for more papers by this authorYi-Hsiang Hsu, Yi-Hsiang Hsu Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, USA Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USASearch for more papers by this authorHouxun Xing, Houxun Xing Institute of Biomedicine, Anhui Medical University, Hefei, ChinaSearch for more papers by this authorXiaobin Wang, Xiaobin Wang The Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Chicago, IL, USASearch for more papers by this authorXiping Xu, Xiping Xu Institute of Biomedicine, Anhui Medical University, Hefei, China Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USASearch for more papers by this author Shanqun Jiang, Corresponding Author Shanqun Jiang School of Life Sciences, Anhui University, Hefei, China Institute of Biomedicine, Anhui Medical University, Hefei, China Correspondence Shanqun Jiang, PhD., School of Life Sciences, Anhui University, 3 Feixi Road, PO Box 41, Hefei 230039, China. Tel.: 86-13956059590 Fax: 86-551-5107354 E-mail: shanqun@gmail.comSearch for more papers by this authorQianru Chen, Qianru Chen School of Life Sciences, Anhui University, Hefei, ChinaSearch for more papers by this authorScott A. Venners, Scott A. Venners Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CanadaSearch for more papers by this authorGuisheng Zhong, Guisheng Zhong Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USASearch for more papers by this authorYi-Hsiang Hsu, Yi-Hsiang Hsu Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, USA Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, USASearch for more papers by this authorHouxun Xing, Houxun Xing Institute of Biomedicine, Anhui Medical University, Hefei, ChinaSearch for more papers by this authorXiaobin Wang, Xiaobin Wang The Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Chicago, IL, USASearch for more papers by this authorXiping Xu, Xiping Xu Institute of Biomedicine, Anhui Medical University, Hefei, China Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USASearch for more papers by this author First published: 18 July 2013 https://doi.org/10.1111/1755-5922.12002Citations: 16AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Objective We investigate the effect of simvastatin on plasma homocysteine (Hcy) levels and whether genetic factor affects the effect of simvastatin. Methods A total of 338 patients with hyperlipidemia were enrolled. Simvastatin was orally administered at a dose of 20 mg/day for 8 weeks. Plasma Hcy levels were measured by high-performance liquid chromatography at baseline and after 8 weeks of treatment. Genotyping of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism was performed by TaqMan probe technique. Results Serum total Hcy levels were positively correlated with serum creatinine (r = 0.332, P < 0.001). Among total subjects, simvastatin treatment resulted in a significant reduction in serum Hcy levels after 8 weeks (−0.37 ± 2.21 μmol/L, P = 0.003), and this effect was dependent on the initial levels of serum Hcy. The individuals with 677TT genotype had a significantly higher baseline Hcy level and a greater change in Hcy levels. After stratification by body mass index (BMI), we observed a significant increase in Hcy levels among the TT genotype group in adjusted model (beta±SE: 2.64 ± 0.84 μmol/L; P = 0.002) among patients with BMI ≥ 25 (kg/m2). Conclusions Simvastatin can cause a marked decrease in plasma Hcy levels. MTHFR C677T genetic variant contributes to simvastatin's effects among Chinese subjects with primary hyperlipidemia. Introduction Homocysteinemia and hyperlipidemia are two major risk factors associated with the occurrence of atherosclerotic vascular disease 1, 2. Plasma levels of Hcy were related to the cholesterol in homocysteinemic patients as well as in HepG2 cells and experimental animals 3. Methionine administration to pathogenic control rats significantly increased the levels of Hcy, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), very low-density lipoprotein-cholesterol (VLDL-C), and triglyceride (TG) and decreased the levels of high-density lipoprotein-cholesterol (HDL-C) in serum 4, 5. In contrast to these studies, most of the epidemiological data indicated that the elevation of plasma Hcy was not associated with a significant change in plasma TC but negatively associated with HDL-C 6-8. These contradictory findings may come from the unclear interactions between Hcy and lipid metabolism, and thus identifying the mechanisms linking Hcy and lipid metabolism is necessary to resolve the controversy. Statins are widely used to prevent cardiovascular disease through the reduction in TC and especially LDL-C. In addition to blocking 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase involved in cholesterol synthesis, statins possess numerous pleiotropic properties including 9 (1) nitric oxide-mediated improvement in endothelial dysfunction and upregulation of endothelin-1 expression; (2) antioxidant effects; (3) anti-inflammatory properties. Atorvastatin may inhibit Hcy-induced reactive oxygen species accumulation and endothelium cell apoptosis through the NADPH oxidase and/or Nox4/p38MAPK-dependent mechanism 10, 11. Simvastatin attenuated Hcy-induced human umbilical vein endothelial cells apoptosis and caspase-3 activation by upregulating c-IAP1 and c-IAP2 expressions 12. These findings suggest that statins can decrease plasma Hcy level by affecting endothelial function. The effects of simvastatin are not consistent. Studies have shown that higher doses of simvastatin (i.e., 80 mg daily) produced a significant reduction in serum Hcy levels in patients with hypercholesterolemia 13, 14. Recently, treatment with statins in women with polycystic ovary syndrome (PCOS) leads to decreases in serum Hcy levels 15. In contrast to these studies, the neutral effect of therapeutic dosages of either atorvastatin or simvastatin was proposed on Hcy levels in multiple studies 16-20. The different effects of statins on Hcy levels may be due to the small number of patients, differences in the drug doses and treatment periods. Thus, studies with large numbers of participants will be necessary to prove this effect for single statin on Hcy levels. The metabolism of Hcy is under genetic control. MTHFR is an enzyme involved in Hcy metabolism. The 677TT genotype is related to a lower MTHFR activity, a reduced remethylation of Hcy to methionine, and a higher Hcy level 21, 22. For individuals with the TT genotype, the effect of folate on the metabolism of Hcy can lead to a larger decrease in Hcy level than for those without TT genotype 23-25. As statins influence Hcy concentrations, there may be an interaction between C677T in the MTHFR gene and statin therapy in the Hcy-lowering efficacy. In this study, we examined the effect of simvastatin on plasma Hcy levels in a cohort of primary hyperlipidemic patients and whether the genetic factor contribute to the changes in Hcy levels after simvastatin treatment. Patients and Methods Study Population Totally 353 patients were recruited for the study from Anqing region, China. Men and women with dyslipidemia were screened for eligibility by medical history, physical examination, and clinical laboratory evaluation, including the lipid profile. No participant had either symptomatic ischemic heart disease or any other vascular disease. Any lipid-lowering medications had to have been discontinued for at least 4 weeks. All participants gave informed consent, and the study protocol was approved by the ethics committee of Institute of Biomedicine, Anhui Medical University. Participants who met the following criteria of fasting serum lipid level were recruited as primary hyperlipidemia: TC: 5.72–8.32 mmol/L and/or LDL: 3.64–6.50 mmol/L and TG ≥ 1.70 mmol/L. To avoid potentially severe adverse effects, patients with (1) impaired hepatic function (aminotransferase levels > 2 × normal and history of chronic liver disease, such as cirrhosis or alcohol abuse), (2) impaired renal function (serum creatinine levels > 1.8 mg/dL, and/or a history of chronic renal disease, such as glomerulonephritis, chronic pyelonephritis, obstructive renal disease, or proteinuria), (3) diabetes mellitus (fasting blood glucose > 126 mg/dL), (4) raised thyroid-stimulating hormone (TSH) levels (>5.0 μU/L), and (5) any medical conditions that might preclude successful completion were excluded from the study. Simvastatin Treatment After a washout period of 7–10 days, all subjects were treated orally with simvastatin at a daily fixed dosage of 20 mg for eight consecutive weeks. Subjects were required to take their simvastatin between 8:00 am and 10:00 am. During treatment, subjects were required to visit our clinical center every 2 weeks for blood lipid examination and to report any adverse effects. Those receiving drugs possibly affecting the laboratory parameters tested were excluded. Blood samples were taken after a 14-h overnight fast for the determination of serum urea, creatinine, glucose, lipids, Hcy levels, as well as liver and muscle enzymes at baseline and at 8 weeks following treatment initiation. Laboratory Determinations Venous blood samples were drawn and collected in ethylenediaminetetraacetic acid (EDTA) tubes after a 14-h fast at 8.00 am to 10.00 am. The samples were then centrifuged at 2500 g for 10 min to obtain the serum. In our analytical center, automated biochemical analysis was used for the laboratory determinations. Levels of TC, HDL-C, LDL-C, and TG were determined with enzymatic colorimetric assays (Roche Diagnostics, Mannheim, Germany). The intra-assay and inter-assay coefficients of variation were < 5% for all assays were performed. Total plasma Hcy levels were measured by high-performance liquid chromatography (HPLC, Agilent HP 1100 type) coupled with a fluorescence detector (HP 1046 type). The chromatographic column was Hypersil C18 (4.6 mm × 250 mm, 5 μm). We used a 0.07 mol/L HAc buffer as the mobile phase with a flow-rate of 0.8 mL/min. The injection volume was 15 μL. The column temperature was 25°C. The analysis time was 15 min. The excitation and emission wavelengths were set at 390 and 470 nm, respectively. The intra-assay and inter-assay coefficients of variation were < 2%. Genotyping of MTHFR C677T TaqMan allelic discrimination technique was used for detecting MTHFR C677T (rs1801133) genotype in our central laboratory. Universal reaction conditions for genotyping were as follows: 4 ng dried DNA, 0.08 μL 40 × assay locus-specific probe, and 2.0 μL TaqMan universal polymerase chain reaction (PCR) master mix made to a final volume of 4 μL with 1.92 μL sterile water. The PCR cycle conditions were made of initial denaturation at 95°C for 10 min, followed by 50 cycles of 92°C for 15 s and 60°C for 1 min. Each sample was measured twice, and the concordance rate was 99.7%. Statistical Analysis Epidata 3.1 Chinese version was used for database design, data entry, and data check. Mean ± SD were calculated for continuous variables. The t-test was used to compare quantitative variables between two groups. The chi-square test was used for categorical variables. Paired t-test was used to compare Hcy levels before and after treatment. "Post-treatment minus baseline" changes in serum total Hcy levels and serum lipid levels (TC, TG, HDL and LDL), renal function (serum creatinine and urea), or liver function (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and gamma-glutamyl transpeptidase [GGT]) were defined as the change in clinical parameters. A multivariate linear regression model was used to evaluate the modification effect of baseline Hcy levels, MTHFR C677T polymorphism on the changes in Hcy levels after simvastatin treatment before and after adjusting for possible confounders, including age, gender, and body mass index (BMI). Relationships between variables were assessed by Pearson's correlation coefficient. Differences were considered to be significant at P < 0.05. All the statistical analysis was carried out using the R packages. Results Baseline Characteristics of Participants A total of 353 patients with primary hyperlipidemia were enrolled and prescribed for simvastatin treatment. Of them, 338 subjects with complete information were used in the final data analysis. There were not significant differences for age, BMI, TG, TC, HDL-C, LDL-C, AST, and ALP between the male and female subjects. Males had higher baseline Hcy levels ([10.25 ± 3.21] μmol/L) than females ([8.70 ± 3.60] μmol/L) (P < 0.001). The percentages of hyperhomocysteinemia (Hcy ≥ 10 μmol/L) were 49.0% and 25.8% in male and female patients, respectively (P < 0.001). Significantly higher ALT, GGT, creatinine, and urea levels were observed in males than in females. MTHFR C677T polymorphism did not deviate from Hardy–Weinberg expectation in females (P > 0.05), but not in males. We re-genotyped all the 338 subjects, the genotype distribution was not changed. The distributions of MTHFR C677T genotypes, cigarette smoking, and alcohol drinking were significantly different between males and females (Table 1). Table 1. Baseline characteristics of the subjects Variables Male (n = 146) Female (n = 192) P Age (year) 50.49 ± 8.56 51.13 ± 6.41 0.45 BMI (kg/m2) 23.57 ± 2.53 23.92 ± 3.10 0.26 Height (cm) 163.23 ± 5.84 153.03 ± 5.59 <0.001 Weight (kg) 62.93 ± 8.47 56.09 ± 8.41 <0.001 TG (mmol/L) 1.78 ± 1.23 1.90 ± 0.97 0.37 TC (mmol/L) 6.39 ± 0.52 6.46 ± 0.58 0.27 HDL-C (mmol/L) 1.97 ± 0.53 1.99 ± 0.44 0.72 LDL-C (mmol/L) 3.56 ± 0.78 3.61 ± 0.59 0.94 ALT (mmol/L) 34.63 ± 18.24 29.89 ± 24.42 0.04 AST (mmol/L) 36.37 ± 10.35 34.39 ± 8.96 0.06 ALP (mmol/L) 89.69 ± 20.50 94.82 ± 35.67 0.10 GGT (mmol/L) 42.07 ± 70.80 25.81 ± 28.51 0.01 Creatinine (mmol/L) 79.70 ± 14.19 60.50 ± 9.33 <0.001 Urea (mmol/L) 354.97 ± 74.25 273.74 ± 56.18 <0.001 Baseline Hcy (μmol/L) 10.25 ± 3.21 8.70 ± 3.60 <0.001 <10 74 (51.0) 144 (74.2) <0.001 ≥10 71 (49.0) 50 (25.8) Non-smoker 52 (35.6) 184 (95.8) <0.001 Smoker 94 (64.4) 8 (4.2) Non-drinker 70 (47.9) 181 (94.3) <0.001 Drinker 76 (52.1) 11 (5.7) MTHFR C677T (%) CC 56 (38.4) 62 (32.3) 0.04 CT 80 (54.8) 100 (52.1) TT 10 (6.8) 30 (15.6) TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase. Bold values denotes significant results. Relationships between Variables Assessed by Pearson's Correlation Coefficient At baseline, serum total Hcy levels positively correlated with serum creatinine (r = 0.332, P < 0.001) and inversely with change in Hcy after simvastatin treatment (r = −0.273, P < 0.001) in the whole population. In addition, change in Hcy treated with simvastatin was positively associated with change in creatinine levels (r = 0.127, P = 0.02) (Figure S1). No correlation was found between "post-treatment minus baseline" changes in serum total Hcy levels and serum lipid levels, or liver function (ALT, AST, ALP, and GGT). Effect of Simvastatin Treatment on TG, TC, HDL-C, and LDL-C and Other Clinical Parameters Simvastatin therapy resulted in a significant reduction in TC, LDL-C, and TG concentrations. HDL-C levels were decreased by simvastatin. ALP, GGT, and urea levels were significantly lowered in the simvastatin-treated group. Simvastatin treatment produced significant increases in serum creatinine and AST levels (Table 2). Table 2. Changes in lipid and other clinical parameter levels after simvastatin treatment Group (mmol/L) Before treatment 8 weeks after treatment Change (μmol/L) Change (%) P TG 1.85 ± 1.09 1.23 ± 0.67 −0.62 ± 0.85 −27 ± 30 <0.001 TC 6.43 ± 0.56 4.46 ± 0.67 −1.97 ± 0.69 −31 ± 10 <0.001 HDL-C 2.00 ± 0.48 1.52 ± 0.43 −0.45 ± 0.27 −23 ± 12 <0.001 LDL-C 3.62 ± 0.67 2.38 ± 0.57 −1.25 ± 0.61 −33 ± 24 <0.001 ALT 31.92 ± 22.10 32.56 ± 17.29 0.64 ± 22.20 13 ± 54 0.6 AST 35.24 ± 9.62 38.50 ± 12.43 3.26 ± 11.46 13 ± 35 <0.001 ALP 92.63 ± 30.20 80.36 ± 24.80 −12.26 ± 17.10 −11 ± 28 <0.001 GGT 32.77 ± 51.62 28.45 ± 59.04 −4.32 ± 21.19 −9 ± 32 <0.001 Creatinine 68.71 ± 15.03 70.73 ± 13.97 2.01 ± 5.48 4 ± 8 <0.001 Urea 308.48 ± 75.96 298.45 ± 73.41 −10.03 ± 43.03 −2 ± 15 <0.001 TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase.Bold values denotes significant results. Effect of Simvastatin Treatment on Hcy Levels Hcy levels were significantly decreased in patients receiving simvastatin in the total population (−0.37 ± 2.21 μmol/L, P = 0.003) (Figure 1). Stratified by baseline Hcy levels, the patients with baseline Hcy < 10 μmol/L had no significant change in plasma Hcy levels (P = 0.93). By contrast, those with baseline Hcy ≥ 10 μmol/L had a markedly reduction in plasma Hcy levels (−1.04 ± 3.05 μmol/L, P < 0.001) (Figure 1). Multivariate linear regression further identified that compared with patients with baseline Hcy < 10 μmol/L, those with baseline Hcy ≥ 10 μmol/L had a significantly lower change in Hcy levels after simvastatin treatment in either unadjusted (beta ± SE: −1.05 ± 0.24; P < 0.001) or adjusted (beta ± SE: −1.08 ± 0.26; P < 0.001) regression model (Table 3). Figure 1Open in figure viewerPowerPoint Effect of Simvastatin treatment on change in Hcy levels. Change in Hcy levels (Mean ± SED) before and after treatment was compared by paired t-test Significantly different from pretreatment **P < 0.01. In total population, Hcy levels were significantly decreased in patients receiving simvastatin (−0.37 ± 2.21 μmol/L, P = 0.003). The patients with baseline Hcy < 10 μmol/L had no significant change in plasma Hcy levels (P = 0.93). The patients with baseline Hcy ≥ 10 μmol/L had a marked reduction in plasma Hcy levels (−1.04 ± 3.05 μmol/L, P < 0.001). Table 3. Multivariate linear regression of the baseline Hcy level modification effect on the changes of Hcy levels after Simvastatin treatment Group (μmol/L) n Hcy change Unadjusted Adjustedaa Adjusted for age, sex, BMI, smoking, and alcohol consumption.Bold values denotes significant results. β SE P β SE P Baseline Hcy < 10 217 0.01 ± 1.44 Ref Ref Baseline Hcy ≥ 10 121 −1.04 ± 3.05 −1.05 0.24 <0.001 −1.08 0.26 <0.001 a Adjusted for age, sex, BMI, smoking, and alcohol consumption.Bold values denotes significant results. Modification Effect of MTHFR C677T Polymorphism on the Changes in Hcy Levels after Simvastatin Treatment Among total subjects, the baseline Hcy levels for CC, CT, and TT genotypes were (8.72 ± 2.95), (9.27 ± 3.17), and (11.59 ± 5.29) μmol/L, respectively. Subjects with the TT genotype not only had higher baseline Hcy levels (P < 0.001), but also had a greater change in Hcy levels after 8 weeks of simvastatin treatment in either unadjusted (beta±SE: 0.79 ± 0.40; P = 0.05) or adjusted (beta±SE: 0.82 ± 0.41; P = 0.04) models. After stratification by BMI, we observed that those with the TT genotype had a more significant increase in Hcy levels after simvastatin treatment in either unadjusted (beta ± SE: 2.30 ± 0.80; P = 0.007) or adjusted (beta±SE: 2.64 ± 0.84; P = 0.002) models among patients with BMI ≥ 25 (kg/m2). However, among the BMI < 25 (kg/m2) group, no effect of MTHFR C677T polymorphism on change in Hcy levels was found (Table 4). Table 4. Modification effect of MTHFR C677T polymorphism on the changes in Hcy levels after Simvastatin treatment stratified by BMI Genotype n Baseline Hcy (μmol/L) Hcy change Unadjusted Adjustedaa Adjusted for age, sex, BMI, smoking, and alcohol consumption.Bold values denotes significant results. β SE P β SE P Total CC 118 8.72 ± 2.95 −0.52 ± 1.98 Ref Ref CT 180 9.27 ± 3.17 −0.41 ± 1.76 0.10 0.26 0.7 0.11 0.26 0.68 TT 40 11.59 ± 5.29 0.28 ± 3.94 0.79 0.4 0.05 0.82 0.41 0.04 BMI<25 CC 78 8.51 ± 2.51 −0.25 ± 1.72 Ref Ref CT 135 9.19 ± 3.10 −0.48 ± 1.63 −0.22 0.28 0.43 −0.27 0.28 0.34 TT 25 11.56 ± 4.77 −0.27 ± 3.57 −0.01 0.44 0.97 −0.06 0.45 0.89 BMI≥25 CC 40 9.15 ± 3.70 −1.04 ± 2.37 Ref Ref CT 45 9.51 ± 3.38 −0.23 ± 2.09 0.81 0.58 0.17 0.94 0.60 0.12 TT 15 11.64 ± 6.27 1.22 ± 4.49 2.300 0.804 0.007 2.64 0.84 0.002 a Adjusted for age, sex, BMI, smoking, and alcohol consumption.Bold values denotes significant results. Discussion This is the first study to detect the change in Hcy levels after simvastatin treatment in Chinese primary hyperlipidemia. The relatively large number of subjects is a prominent advantage, due to which our findings had more statistical power than many previous studies of smaller sample sizes 15-22. Nonetheless, these findings need to be replicated and expanded to a larger population of primary hyperlipidemic individuals to understand the effect of lipid-lowering treatment on Hcy levels. Hcy can cause endothelial damage and oxidative stress and thus hyperhomocysteinemia may be an independent risk factor for vascular diseases. Apart from their lipid-lowering capacity, statins exert anti-inflammatory and antioxidant effects. The anti-inflammatory and antioxidant capacity of statins is thought to contribute to the Hcy-lowering beneficial effects in patients 26. In this study, we identified the effects of simvastatin treatment on Hcy levels in patients with primary hyperlipidemia. Our results suggested that simvastatin treatment were effective not only in improving the lipid profile (reducing TC, TG, and LDL-C levels), but also in reducing nonlipid biochemical risk factors such as Hcy levels. Animal experimental studies showed that atorvastatin significantly decreased the levels of Hcy, TC, TG, LDL-C, and VLDL-C and increased the serum levels of HDL-C in hyperhomocysteinemic rats 4, 5. Simvastatin can significantly decrease serum Hcy levels by augmenting renal function, decreasing microalbuminuria, improving renal allograft survival, and a fall in blood pressure 27, 28. Our findings supported the view that the simvastatin treatment interfered with creatinine metabolism, because a hypohomocysteinemic effect of simvastatin was positively associated with a decrease in creatinine levels (r = 0.127, P = 0.02). However, the exact pathophysiological mechanisms underlying the association of serum Hcy change with statins remain to be further elucidated. Lipid-lowering agents are known to modify the concentration of plasma Hcy. In a meta-analysis of 15 studies, statins caused small reductions (−3.5%) in Hcy blood concentrations, but the clinical relevance of these small effects is not clear 29. Milionis et al. 16 proposed the neutral effect of therapeutic dosages of either atorvastatin or simvastatin on Hcy levels in patients with primary hyperlipidemia. The finding is in agreement with the small number of studies evaluating the influence of statin therapy on Hcy levels 17-20. A prospective study designed by Luftjohann et al. 13 demonstrated that a higher dose of simvastatin produced a significant reduction in serum Hcy levels in patients with hypercholesterolemia. Vladimirova-Kitova et al. 14 compared the effects of moderate (40 mg) to high (80 mg) simvastatin doses on total Hcy levels in patients with hypercholesterolemia and found that the therapy with 80 mg, but not 40 mg, simvastatin significantly decreased the total Hcy level. More recently, Kaya et al. 15 randomly divided into two groups for treatment with atorvastatin and simvastatin. After 12 weeks of treatment, serum Hcy levels in the atorvastatin group decreased from 14.3 ± 2.9 to 10.6 ± 1.7 μmol/L; in the simvastatin group, the levels decreased from 13.6 ± 2.1 to 11.1 ± 1.9 μmol/L. Their findings demonstrated that treatment with statins in women with PCOS leads to decreases in serum Hcy levels. Similar to several previous studies 13-15, we found a significant decrease in Hcy levels after simvastatin treatment for 8 weeks (P = 0.003). Importantly, stratified by baseline Hcy levels, we found that those with baseline Hcy ≥ 10 μmol/L had a significant decrease in plasma Hcy levels (P < 0.001), whereas those with baseline Hcy < 10 μmol/L had no change in plasma Hcy levels after treatment. The basis for our study to define hyperhomocysteinemia as Hcy ≥10 μmol/L was from the American Heart Association/American Stroke Association (AHA/ASA) guidelines for the prevention of stroke in patients with ischemic stroke (IS) or transient ischemic attack (TIA) in 2006. Moreover, many epidemiological and clinical studies also revealed that the risk of developing cardiovascular disease increased significantly when plasma Hcy level was more than 10 μmol/L. Further, we did a multivariate linear regression and estimated a modification effect of the baseline Hcy level on the changes in Hcy levels after simvastatin treatment and provided further support for the conclusion that subjects with baseline Hcy ≥ 10 μmol/L had significantly lower changes in Hcy levels (adjusted beta±SE: -1.08 ± 0.26, P < 0.001). Our data showed that if the initial serum Hcy concentration is different, simvastatin will have distinct effects. Indeed, in some previous studies 13-15, the baseline Hcy level was relatively higher (13.0–15.5) μmol/L and this would lead to the efficient therapy of simvastatin. Whereas in other studies 16-20, the baseline Hcy level was lower (around 10.5 μmol/L), and simvastatin treatment was consequently less efficient. Our findings provide important insights to the mechanism of simvastatin on serum Hcy. In the study of Giral et al. 18, it was identified that changes in Hcy levels in response to atorvastatin were heterogeneous, particularly in one patient who showed a 75% increase in Hcy level, which meant that this may be explained by genetic variants. A common C677T polymorphism in the MTHFR gene plays a vital role in regulating serum Hcy levels. The MTHFR C677T can interact with statin therapy to influence the change in Hcy levels and further modify the risk of cardiovascular outcomes. Maitland-van et al. 30 found that the MTHFR 677 CC variant appeared to modify the efficacy of pravastatin in reducing risk of cardiovascular events [0.71 (95% CI: 0.58-0.87)]. Recently, a small sample-sized, placebo-controlled study 31 showed that statin therapy significantly decreased the Hcy concentration, but the decreased Hcy levels were not modified by the MTHFR polymorphism. Fan et al. 32 found that the observed changes in Hcy concentrations with antihypertension medications were independent of MTHFR polymorphisms. However, our study found that the MTHFR C677T polymorphism remarkably modified the changes in Hcy levels among total cohort subjects. After stratification by BMI, we found that the 677TT subjects with BMI ≥ 25 kg/m2 had a more significant increase in Hcy levels after simvastatin treatment compared to the CC genotype. The increase in BMI was associated with elevated Hcy levels and reduced vitamin levels among hypertensives 33. A previous study showed that simvastatin treatment may result in reduction of plasma antioxidant vitamins 34. Our results imply that the reduced vitamin status after simvastatin treatment might explain the elevation in Hcy levels, especia